Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Thoracic 3Other hematologic neoplasm 3Dermatologic 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × obatoclax × Thoracic × Clear all
NCT00405951 2016-07-21

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
47 enrolled
Thoracic

Lung Neoplasms

NCT00682981 2016-07-21

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
218 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01563601 2012-08-15

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡